Avid initiates first Phase II Alzheimer’s disease trial
Avid’s 18F-AV-45 is used with positron emission tomography (PET) to allow visualization of the amyloid plaque deposits in the brain that are characteristic of Alzheimer’s disease. This US
The US Food and Drug Administration (FDA) has granted priority review to Roche’s supplemental biologics licence application (sBLA) for Gazyva/Gazyvaro (obinutuzumab) to treat adults with primary membranous nephropathy (pMN).
Arpeggio, performed in 60 centers, throughout 12 countries, was a double-blind, randomized, parallel-group, fixed-dose, two-arm, controlled trial (rimonabant 20mg/once daily versus control). Patients had type 2 diabetes treated